Senior reporter covering neuroscience, M&A and cutting-edge drug technologies for @biopharmadive. Formerly @TheStreet, @educationweek, @mcclatchydc.
Joined December 2011
- Tweets 13,760
- Following 431
- Followers 2,176
- Likes 4,065
529 Photos and videos
Pinned Tweet
1 Jul 2024
In case you missed it, our latest feature takes a deep dive into a very interesting area of drug research: ion channels. These proteins made $VRTX one of the world's wealthiest biotechs. Now others are getting in on the action. #biotech #science #biopharma biopharmadive.com/news/ion-c…
1
3
1,123
Jacob Bell retweeted
May 22
Parkinson’s drug from Biogen, Denali comes up short biopharmadive.com/news/bioge… $BIIB $DNLI by @realJacobBell
1
432
Jacob Bell retweeted
May 15
Jacob is a masterful storyteller and this feature from last year is a good example.
ASBPE agrees - Jacob's story won National Gold for best feature and anchored a portfolio they judged to be "best body of work by a staff journalist" (announced y'day).
Give it a read!
May 15
In one of my features (linked below), I chronicled the agonizing journey a couple patients went through trying to keep their cancer pain in check. biopharmadive.com/news/cance…
2
6
913
May 15
Extremely proud to say the American Society of Business Publication Editors awarded me Best Body of Work by a Staff Journalist and Best Feature at their national awards ceremony yesterday. @ASBPE
1
4
113
May 15
The work is, of course, far from finished. If you have ideas for a story that needs telling, please reach out. Thank you to my BioPharma Dive team, whose support gave me the bandwidth to investigate this topic and write these stories.
1
1
62
May 15
And thank you to @ASBPE for these honors, I really can't express how much they mean (probably not the best admission for a writer).
1
56
Jacob Bell retweeted
May 12
Read this Deep Dive for @realJacobBell 's excellent scientific and business reporting, and for one of the best outro quotes I've read in awhile.
May 12
A year ago, $VRTX hit a scientific milestone in bringing a new pain medicine to market. Since then, the buzz surrounding it has subsided amid questions about its usefulness. @realJacobBell has more in this deep look at the state of pain drug research.
biopharmadive.com/news/pain-…
1
5
596
Jacob Bell retweeted
Mar 18
RBC: Revolution, Xenon, Arrowhead among top #biotech takeover targets biopharmadive.com/news/biote… by @realJacobBell $ARWR $XENE $RVMD $DYNE
1
4
8
2,962
Jacob Bell retweeted
NEW
FDA vaccines chief Vinay Prasad will leave the agency at the end of April
Gift link below
16
74
271
104,173
Feb 24
BioMarin has chosen to pull its once highly anticipated gene therapy for hemophilia from the market. The therapy struggled commercially, which led $BMRN to search for a potential buyer. In the company's latest earnings, it reveals it couldn't find one.
1
360
Feb 24
This is an incredible ending for a therapy I've followed for years. If you're interested in the backstory, here's a feature from 2020, when the FDA issued an astonishing rejection to Roctavian's approval application. biopharmadive.com/news/hemop…
128
Feb 24
In a new note, RBC Capital Markets analyst Brian Abrahams poses a question: Could Neurocrine Biosciences be a takeout target? $NBIX
1
1
269
Feb 24
So, Abrahams writes, while $NBIX hasn't often been seen as a takeout target, if this gap continues between where investors vs. analysts value the stock, Neurocrine could certainly be attractive to a large pharma acquirer.
1
148
Feb 24
$NBIX "has the scarcity value of being one of only several biotech companies whose ~$3B in existing commercial revenue is expected to grow by more than 50% by 2030 and be durable well into the next decade," he wrote.
117
Feb 23
"The biggest hurdle, though, is moving beyond a first in human trial to regulatory approval. Getting past that gap is what allows treatments to become commercially available, reimbursed and scaled so all patients who need them can access them ... "
1
74
Feb 23
"This is why clear, pragmatic, consistent regulatory guidance is essential. The types of individualized genetic therapies that we're trying to develop simply do not fit in the traditional model of drug development."
60